Artelo Biosciences Inc

Artelo Biosciences’ stock fell 6.1% last month as investors weigh its negative earnings, low market cap and challenges in endocannabinoid‑system therapy development.

Artelo Biosciences has made a pioneering move by adopting Solana as a core reserve asset, marking the first publicly-traded pharmaceutical company to do so, and potentially setting a precedent for the industry.

Artelo Biosciences, Inc. is a forward-looking biopharmaceutical innovator dedicated to developing and commercializing novel therapeutics targeting the endocannabinoid system.

Artelo Biosciences’ stock price surged 135% after announcing positive results from a Phase 1 study of its non-opioid pain treatment candidate, ART26.12.

Artelo Biosciences, Inc. is a pioneering biopharmaceutical company focused on developing innovative therapeutics targeting the endocannabinoid system, with a promising pipeline and strategic partnerships aimed at addressing unmet medical needs in pa…

Artelo Biosciences Inc. has made headlines with promising research on ART26.12, a potential treatment for psoriasis, amidst significant market activity and increased short interest in its stock.